Rhythm (RYTM) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.73
- EPS estimate
- −$0.81
- EPS surprise
- +9.56%
- Revenue surprise
- +5.32%
- Revenue
- $71.3M
- Revenue estimate
- $67.7M
- Reported
- Aug 4, 2026
Rhythm Pharmaceuticals reported Q2 2026 results on August 4, 2026. It posted a loss of $0.73 per share, narrower than the expected loss of $0.81, a beat of 9.56%. Revenue was $71.3 million, above the $67.7 million estimate by about 5%. Compared with Q2 2025, the loss narrowed from $0.75 per share and revenue rose about 47% from $48.5 million.
Every quarter in the table is a loss. The annual loss per share was $3.48 in 2022, $3.20 in 2023, $4.35 in 2024 and $3.11 in 2025. The 2024 total includes the largest quarterly loss in the table, $2.35 in Q1 2024. Most other quarters lost between about $0.70 and $0.90 per share. Revenue has grown fast from a small base: $23.7 million in 2022, $77.4 million in 2023, $130.2 million in 2024 and $189.8 million in 2025. It has risen in each quarter since Q1 2025, and Q2 2026 was the highest in the table. Rhythm beat the EPS estimate in 11 of the last 20 quarters.
Rhythm reported its third quarter between November 2 and November 8 in each of the past five years. That points to early November 2026 for the next report.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | −$0.81 | −$0.73 | +9.56% | $71.3M | SEC |
| Q1 2026 | May 5, 2026 | −$0.83 | −$0.83 | −0.61% | $60.1M | SEC |
| Q4 2025 | Feb 26, 2026 | −$0.80 | −$0.73 | +9.26% | $57.3M | SEC |
| Q3 2025 | Nov 4, 2025 | −$0.71 | −$0.82 | −15.80% | $51.3M | SEC |
| Q2 2025 | Aug 5, 2025 | −$0.67 | −$0.75 | −11.92% | $48.5M | SEC |
| Q1 2025 | May 7, 2025 | −$0.69 | −$0.81 | −16.68% | $32.7M | SEC |
| Q4 2024 | Feb 26, 2025 | −$0.69 | −$0.72 | −3.81% | $41.8M | SEC |
| Q3 2024 | Nov 5, 2024 | −$0.80 | −$0.73 | +9.26% | $33.3M | SEC |
| Q2 2024 | Aug 6, 2024 | −$0.71 | −$0.55 | +22.42% | $29.1M | SEC |
| Q1 2024 | May 7, 2024 | −$2.36 | −$2.35 | +0.27% | $26.0M | SEC |
| Q4 2023 | Feb 22, 2024 | −$0.71 | −$0.70 | +0.79% | $24.2M | SEC |
| Q3 2023 | Nov 7, 2023 | −$0.74 | −$0.76 | −2.70% | $22.5M | SEC |
| Q2 2023 | Aug 1, 2023 | −$0.80 | −$0.82 | −2.78% | $19.2M | SEC |
| Q1 2023 | May 2, 2023 | −$0.72 | −$0.92 | −28.22% | $11.5M | SEC |
| Q4 2022 | Mar 1, 2023 | −$0.81 | −$0.75 | +7.28% | $8.8M | SEC |
| Q3 2022 | Nov 8, 2022 | −$1.00 | −$0.79 | +20.91% | $4.3M | — |
| Q2 2022 | Aug 2, 2022 | −$0.96 | −$0.89 | +6.81% | $9.1M | — |
| Q1 2022 | May 3, 2022 | −$1.01 | −$1.05 | −3.62% | $1.5M | — |
| Q4 2021 | Mar 1, 2022 | −$0.91 | −$0.85 | +6.89% | $1.8M | — |
| Q3 2021 | Nov 2, 2021 | −$0.81 | −$0.70 | +13.23% | $1.0M | — |
Quarterly revenue
Frequently asked questions
When did Rhythm (RYTM) last report earnings?
Rhythm last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did RYTM beat earnings estimates?
Yes. Rhythm reported EPS of −$0.73 for Q2 2026 against a −$0.81 estimate — a 9.56% beat.
How much revenue did RYTM report last quarter?
Rhythm reported $71.3M in revenue for Q2 2026, against a consensus estimate of $67.7M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.